Protective effects of oxymatrine on experimental diabetic nephropathy

Planta Med. 2014 Mar;80(4):269-76. doi: 10.1055/s-0033-1360369. Epub 2014 Feb 17.

Abstract

Diabetic nephropathy, one of the most common and serious vascular complications of both type 1 and type 2 diabetes mellitus, has become a major contributor of end-stage renal failure. The aims of this study were to investigate the effects and possible underlying action mechanism(s) of oxymatrine on renal damage in diabetic rats. Diabetes was induced in male Sprague-Dawley rats by administering a high-fat diet and an intraperitoneal 30 mg/kg streptozotocin injection. The animals were treated orally with saline, metformin hydrochloride, and oxymatrine at 50, 100, and 150 mg/kg/day for 11 weeks. At the end of the treatment, renal tissue, blood, and urine samples were collected for histological and biochemical examination. The results revealed that oxymatrine significantly decreased blood glucose, urinary protein and albumin excretion, serum creatinine, and blood urea nitrogen in diabetic rats, and ameliorated diabetes-induced glomerular and tubular pathological changes. Furthermore, oxymatrine significantly prevented oxidative stress and reduced the contents of renal advanced glycation end products, transforming growth factor-β1, connective tissue growth factor, and inflammatory cytokines in diabetic rats. All these results indicate that oxymatrine has protective effects on experimental diabetic nephropathy by multiple mechanisms.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Albuminuria / prevention & control
  • Alkaloids / pharmacokinetics
  • Alkaloids / therapeutic use*
  • Animals
  • Blood Glucose / metabolism
  • Blood Urea Nitrogen
  • Connective Tissue Growth Factor / metabolism
  • Creatinine / blood
  • Cytokines / metabolism
  • Diabetes Mellitus, Experimental / complications*
  • Diabetes Mellitus, Experimental / drug therapy
  • Diabetic Nephropathies / drug therapy*
  • Diabetic Nephropathies / metabolism
  • Diabetic Nephropathies / pathology
  • Glycation End Products, Advanced / metabolism
  • Kidney / drug effects*
  • Kidney / metabolism
  • Kidney / pathology
  • Kidney Glomerulus / drug effects
  • Kidney Glomerulus / pathology
  • Kidney Tubules / drug effects
  • Kidney Tubules / pathology
  • Male
  • Oxidative Stress / drug effects
  • Phytotherapy*
  • Plant Extracts / pharmacology
  • Plant Extracts / therapeutic use*
  • Proteinuria / prevention & control
  • Quinolizines / pharmacokinetics
  • Quinolizines / therapeutic use*
  • Rats
  • Rats, Sprague-Dawley
  • Sophora / chemistry*
  • Transforming Growth Factor beta1 / metabolism

Substances

  • Alkaloids
  • Blood Glucose
  • Cytokines
  • Glycation End Products, Advanced
  • Plant Extracts
  • Quinolizines
  • Transforming Growth Factor beta1
  • Connective Tissue Growth Factor
  • oxymatrine
  • Creatinine